To investigate the possible involvement of betel-quid chewing in adipocyte dysfunction, we determined the effects of
arecoline, a major
alkaloid in areca nuts, on adipogenic differentiation (adipogenesis), lipolysis, and
glucose uptake by fat cells. Using mouse 3T3-L1 preadipocytes, we showed that
arecoline inhibited adipogenesis as determined by oil droplet formation and adipogenic marker gene expression. The effects of
arecoline on lipolysis of differentiated 3T3-L1 adipocytes were determined by the
glycerol release assay, indicating that
arecoline induced lipolysis in an
adenylyl cyclase-dependent manner. The diabetogenic effects of
arecoline on differentiated 3T3-L1 adipocytes were evaluated by the
glucose uptake assay, revealing that > or = 300 microM
arecoline significantly attenuated
insulin-induced
glucose uptake; however, no marked effect on basal
glucose uptake was detected. Moreover, using 94 subjects that were randomly selected from a health check-up, we determined the association of betel-quid chewing with
hyperlipidemia and its related risk factors.
Hyperlipidemia frequency and serum
triglyceride levels of betel-quid chewers were significantly higher than those of non-betel-quid chewers. In this study, we demonstrated that
arecoline inhibits adipogenic differentiation, induces
adenylyl cyclase-dependent lipolysis, and interferes with
insulin-induced
glucose uptake.
Arecoline-induced fat cell dysfunction may lead to
hyperlipidemia and
hyperglycemia/
insulin-resistance. These findings provide the first in vitro evidence of betel-quid chewing modulation of adipose cell metabolism that could contribute to the explanation of the association of this habit with
metabolic syndrome disorders.